Integer Holdings Corporation (NYSE:ITGR), a leading medical device
outsource manufacturer, today announced results for the three and
six months ended June 28, 2019.
Second Quarter 2019 Highlights (compared to Second
Quarter 2018)
- GAAP and Non-GAAP sales from continuing operations were $314
million, flat with prior year.
- GAAP income from continuing operations increased $5 million to
$28 million, an increase of 22%. Non-GAAP adjusted income
from continuing operations increased $6 million to $41 million, an
increase of 17%.
- Adjusted EBITDA from continuing operations increased $4 million
to $75 million, an increase of 6%.
- GAAP diluted EPS from continuing operations increased $0.15 per
share to $0.85 per share, an increase of 21%. Non-GAAP
adjusted diluted EPS from continuing operations increased $0.17 per
share to $1.23 per share, an increase of 16%.
- Paid down $50 million of debt, reducing total outstanding debt
to $863 million, achieving a leverage ratio of 3.1x adjusted
EBITDA.
Revised 2019 Full Year Financial Guidance
- Increased adjusted EBITDA guidance to a range of $277 million
to $285 million.
- Increased GAAP diluted EPS guidance to a range of $2.89 to
$3.09. Increased non-GAAP adjusted diluted EPS guidance to a range
of $4.25 to $4.45.
“Integer delivered strong profit growth in the second quarter,
on flat revenue which was in line with our expectations,” said
Joseph Dziedzic, Integer’s president and chief executive officer.
“Strong cash flow generation enabled continued debt leverage
reduction to 3.1 times adjusted EBITDA. We continue to
execute our operational strategy and have increased our full year
profit outlook,” Mr. Dziedzic continued.
Discussion of Product Line Second Quarter 2019 Sales
(compared to Second Quarter 2018)
- Cardio & Vascular sales increased 1% with strong peripheral
vascular and structural heart growth, offset by the expected impact
of an electrophysiology program maturing life cycle and a supplier
quality related delay.
- Cardiac & Neuromodulation sales decreased 1% due to
difficult prior year comparables and lower growth in
Neuromodulation.
- Advanced Surgical, Orthopedics & Portable Medical includes
sales to the acquirer of our AS&O product line, Viant, under
supply agreements entered into as part of the divestiture. GAAP
sales declined 6%, and non-GAAP sales declined 2% as portable
medical growth is offset by a decline in advanced surgical and
orthopedics products.
- Electrochem sales increased 11% due to energy market demand and
increased customer market penetration.
2019 Outlook(a)(dollars in millions, except per
share amounts)
|
|
GAAP |
|
Non-GAAP(b) |
Continuing Operations: |
|
As Reported |
|
Growth |
|
Adjusted |
|
Growth |
Sales |
|
$1,265 to $1,280 |
|
4% to 5% |
|
$1,265 to $1,280 |
|
4% to 6% |
Income |
|
$95 to $102 |
|
102% to 117% |
|
$140 to $147 |
|
13% to 18% |
EBITDA |
|
N/A |
|
N/A |
|
$277 to $285 |
|
7% to 10% |
Earnings per Diluted
Share |
|
$2.89 to $3.09 |
|
101% to 115% |
|
$4.25 to $4.45 |
|
12% to 17% |
(a) Except as described below, further
reconciliations by line item to the closest corresponding GAAP
financial measure for Adjusted Sales, Adjusted Income, Adjusted
EBITDA, and Adjusted Earnings per Diluted Share (“EPS”), all from
continuing operations, included in our “2019 Outlook” above, are
not available without unreasonable efforts on a forward-looking
basis due to the high variability, complexity and visibility of the
charges excluded from these non-GAAP financial measures.
(b) Adjusted Income and diluted EPS, both from
continuing operations, for 2019 are expected to consist of GAAP
income from continuing operations and diluted EPS from continuing
operations, excluding items such as intangible amortization,
IP-related litigation costs, consolidation and realignment costs,
asset dispositions, severance and loss on extinguishment of debt
totaling approximately $57 million, pre-tax. The after-tax impact
of these items is estimated to be approximately $45 million, or
approximately $1.36 per diluted share.Adjusted EBITDA from
continuing operations is expected to consist of Adjusted income
from continuing operations, excluding items such as depreciation,
interest, stock-based compensation and taxes totaling approximately
$138 million.
Summary of Financial and Product Line Results from
Continuing Operations
(dollars in thousands, except
per share data) |
Three Months Ended |
GAAP |
June 28, 2019 |
|
June 29, 2018 |
|
Change |
|
OrganicGrowth(a) |
Medical Sales |
|
|
|
|
|
|
|
Cardio & Vascular |
$ |
150,397 |
|
|
$ |
148,766 |
|
|
1.1 |
% |
|
1.6 |
% |
Cardiac & Neuromodulation |
114,488 |
|
|
115,941 |
|
|
(1.3 |
)% |
|
(1.3 |
)% |
Advanced Surgical, Orthopedics & Portable Medical |
32,646 |
|
|
34,751 |
|
|
(6.1 |
)% |
|
(2.3 |
)% |
Total Medical Sales |
297,531 |
|
|
299,458 |
|
|
(0.6 |
)% |
|
— |
% |
Non-Medical Sales |
16,663 |
|
|
15,006 |
|
|
11.0 |
% |
|
11.0 |
% |
Total Sales |
$ |
314,194 |
|
|
$ |
314,464 |
|
|
(0.1 |
)% |
|
0.6 |
% |
|
|
|
|
|
|
|
|
Income from continuing
operations |
$ |
28,222 |
|
|
$ |
23,056 |
|
|
22.4 |
% |
|
|
Diluted EPS from continuing
operations |
$ |
0.85 |
|
|
$ |
0.70 |
|
|
21.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
GAAP |
June 28, 2019 |
|
June 29, 2018 |
|
Change |
|
OrganicGrowth(a) |
Medical Sales |
|
|
|
|
|
|
|
Cardio & Vascular |
$ |
302,971 |
|
|
$ |
285,629 |
|
|
6.1 |
% |
|
6.6 |
% |
Cardiac & Neuromodulation |
231,399 |
|
|
224,851 |
|
|
2.9 |
% |
|
2.9 |
% |
Advanced Surgical, Orthopedics & Portable Medical |
64,234 |
|
|
68,692 |
|
|
(6.5 |
)% |
|
(3.6 |
)% |
Total Medical Sales |
598,604 |
|
|
579,172 |
|
|
3.4 |
% |
|
4.0 |
% |
Non-Medical Sales |
30,266 |
|
|
27,718 |
|
|
9.2 |
% |
|
9.2 |
% |
Total Sales |
$ |
628,870 |
|
|
$ |
606,890 |
|
|
3.6 |
% |
|
4.2 |
% |
|
|
|
|
|
|
|
|
Income from continuing
operations |
$ |
49,588 |
|
|
$ |
36,140 |
|
|
37.2 |
% |
|
|
Diluted EPS from continuing
operations |
$ |
1.50 |
|
|
$ |
1.11 |
|
|
35.1 |
% |
|
|
(a) Organic Growth for sales is a Non-GAAP
measure, which excludes foreign currency exchange impact reported
in other income, net and is primarily non-cash and includes the
impact of the long-term supply agreements (“LSAs”) entered into
between the Company and Viant as of the closing of the divestiture
of the AS&O product line. These LSAs govern the sale of
products supplied by Viant to the Company for further resale to
customers and by the Company to Viant for further resale to
customers. Refer to Table C at the end of this release for a
reconciliation of these amounts.
|
Three Months Ended |
Non-GAAP(a) |
June 28, 2019 |
|
June 29, 2018 |
|
Change |
|
OrganicGrowth(b) |
Adjusted EBITDA from continuing operations |
$ |
75,393 |
|
|
$ |
71,354 |
|
|
5.7 |
% |
|
8.6 |
% |
Adjusted income from
continuing operations |
$ |
40,632 |
|
|
$ |
34,744 |
|
|
16.9 |
% |
|
22.4 |
% |
Adjusted diluted EPS from
continuing operations |
$ |
1.23 |
|
|
$ |
1.06 |
|
|
16.0 |
% |
|
21.8 |
% |
|
|
|
|
|
|
|
|
|
Six Months Ended |
Non-GAAP(a) |
June 28, 2019 |
|
June 29, 2018 |
|
YTDChange |
|
OrganicGrowth(b) |
Adjusted EBITDA from
continuing operations |
$ |
141,053 |
|
|
$ |
125,301 |
|
|
12.6 |
% |
|
13.3 |
% |
Adjusted income from
continuing operations |
$ |
73,472 |
|
|
$ |
55,163 |
|
|
33.2 |
% |
|
34.6 |
% |
Adjusted diluted EPS from
continuing operations |
$ |
2.23 |
|
|
$ |
1.69 |
|
|
32.0 |
% |
|
32.7 |
% |
(a) Refer to Tables A and B at the end of this
release for reconciliations of adjusted amounts to the closest
corresponding GAAP financial measures.
(b) Organic Growth for Adjusted EBITDA from
continuing operations, Adjusted income from continuing operations,
and Adjusted diluted EPS from continuing operations are Non-GAAP
measures, which exclude the foreign currency exchange impact
reported in other income, net and is primarily non-cash.
Refer to Table D at the end of this release for a reconciliation of
these amounts.
Conference Call InformationThe
Company will host a conference call on Thursday, August 1, 2019, at
9:00 a.m. ET / 8:00 a.m. CT to discuss these results. The
scheduled conference call will be webcast live and is accessible
through our website at investor.integer.net or by dialing
(833) 236-5762 (U.S.) or (647) 689-4190 (outside U.S.) and the
conference ID is 8118977. The call will be archived on the
Company’s website. An earnings call slide presentation
containing supplemental information about the Company’s results
will be posted to our website at investor.integer.net prior to the
conference call and will be referenced during the conference
call.
About Integer™Integer Holdings
Corporation (NYSE: ITGR) is one of the largest medical device
outsource (MDO) manufacturers in the world serving the cardiac,
neuromodulation, vascular, portable medical and orthopedics
markets. The Company provides innovative, high-quality medical
technologies that enhance the lives of patients worldwide. In
addition, it develops batteries for high-end niche applications in
energy, military, and environmental markets. The Company's brands
include GreatbatchTM Medical, Lake Region MedicalTM and
ElectrochemTM. Additional information is available
at www.integer.net.
Contact InformationTony
BorowiczSVP, Strategy, Business Development & Investor
Relations716.759.5809tony.borowicz@integer.net
Notes Regarding Non-GAAP Financial
InformationIn addition to our results reported in
accordance with generally accepted accounting principles (“GAAP”),
we provide adjusted sales, adjusted income, adjusted earnings per
diluted share, earnings before interest, taxes, depreciation and
amortization (“EBITDA”), adjusted EBITDA, adjusted EBITDA margin,
and organic growth rates, all from continuing operations.
Adjusted income and adjusted earnings per diluted share from
continuing operations consist of GAAP amounts adjusted for the
following to the extent occurring during the period: (i)
acquisition and integration related charges and expenses, (ii)
amortization of intangible assets, (iii) facility consolidation,
optimization, manufacturing transfer and system integration
charges, (iv) asset write-down and disposition charges, (v) charges
in connection with corporate realignments or a reduction in force,
(vi) certain legal expenses, charges and gains, (vii) unusual or
infrequently occurring items, (viii) gain (loss) on equity
investments, (ix) extinguishment of debt charges, (x) the net
impact of the LSAs entered into as of the closing of the
divestiture of the AS&O product line, (xi) the income tax
(benefit) related to these adjustments and (xii) certain tax items
that are outside the normal provision for the period.
Adjusted earnings per diluted share from continuing operations are
calculated by dividing adjusted income from continuing operations
by diluted weighted average shares outstanding. EBITDA from
continuing operations is calculated by adding back interest
expense, GAAP provision (benefit) for income taxes, depreciation
and amortization expense, to income from continuing operations,
which is the most directly comparable GAAP measure. Adjusted
EBITDA from continuing operations consists of EBITDA from
continuing operations plus GAAP stock-based compensation and the
same adjustments as listed above except for items (ii), (ix), (xi)
and (xii).
Adjusted EBITDA margin is adjusted EBITDA as a
percentage of adjusted sales, all from continuing operations.
To calculate organic sales growth rates, we convert current period
sales from local currency to U.S. dollars using the previous
period’s foreign currency exchange rates and exclude the amount of
sales acquired/divested during the period from the current/previous
period amounts, respectively. Adjusted sales from continuing
operations consist of GAAP sales adjusted for item (x) above.
Organic growth rates for Adjusted EBITDA from continuing
operations, Adjusted income from continuing operations and Adjusted
Diluted EPS from continuing operations exclude the impact of
foreign currency exchange gains and losses included in other
(income) loss, net. We believe that the presentation of adjusted
sales, adjusted income, adjusted diluted earnings per share,
EBITDA, adjusted EBITDA, adjusted EBITDA margin, and organic growth
rates, all from continuing operations, provides important
supplemental information to management and investors seeking to
understand the financial and business trends relating to our
financial condition and results of operations.
Forward-Looking StatementsSome
of the statements contained in this press release and other written
and oral statements made from time to time by us and our
representatives are not statements of historical or current fact.
As such, they are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements on our
current expectations, and these statements are subject to known and
unknown risks, uncertainties and assumptions. Forward-looking
statements include statements relating to:
- future sales, expenses, and profitability;
- future development and expected growth of our business and
industry;
- our ability to execute our business model and our business
strategy;
- our ability to identify trends within our industries and to
offer products and services that meet the changing needs of those
markets;
- our ability to remain in compliance with our debt covenants;
and
- projected capital expenditures.
You can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “expects,”
“intends,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or “variations” or the
negative of these terms or other comparable terminology. These
statements are only predictions. Actual events or results may
differ materially from those stated or implied by these
forward-looking statements. In evaluating these statements and our
prospects, you should carefully consider the factors set forth
below. All forward-looking statements attributable to us or persons
acting on our behalf are expressly qualified in their entirety by
these cautionary factors and to others contained throughout this
release.
Although it is not possible to create a
comprehensive list of all factors that may cause actual results to
differ from the results expressed or implied by our forward-looking
statements or that may affect our future results, some of these
factors include the following: our indebtedness, our inability to
pay principal and interest on this outstanding indebtedness or to
remain in compliance with financial and other covenants under our
senior secured credit facilities, and the risk that this
indebtedness limits our ability to invest in our business and
overall financial flexibility; our dependence upon a limited number
of customers; customer ordering patterns; product obsolescence; our
inability to market current or future products; pricing pressure
from customers; our ability to timely and successfully implement
cost reduction and plant consolidation initiatives; our reliance on
third-party suppliers for raw materials, products and
subcomponents; fluctuating operating results; our inability to
maintain high quality standards for our products; challenges to our
intellectual property rights; product liability claims; product
field actions or recalls; our inability to successfully consummate
and integrate acquisitions and to realize synergies and benefits
from these acquisitions and to operate these acquired businesses in
accordance with expectations; our unsuccessful expansion into new
markets; our failure to develop new products including system and
device products; the timing, progress and ultimate success of
pending regulatory actions and approvals; our inability to obtain
licenses to key technology; regulatory changes, including health
care reform, or consolidation in the healthcare industry; global
economic factors including foreign currency exchange rates and
interest rates; the resolution of various legal actions brought
against the Company; enactment related and ongoing impacts related
to the Tax Reform Act, including the GILTI tax; and other risks and
uncertainties that arise from time to time and are described in
Item 1A “Risk Factors” of our Annual Report on Form 10-K and
in our other periodic filings with the SEC. Except as may be
required by law, we assume no obligation to update forward-looking
statements in this press release whether to reflect changed
assumptions, the occurrence of unanticipated events or changes in
future operating results, financial conditions or prospects, or
otherwise.
Condensed
Consolidated Statements of Operations - Unaudited |
|
|
|
|
(in thousands except per share
data) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
June 28, 2019 |
|
June 29, 2018 |
|
June 28, 2019 |
|
June 29, 2018 |
Sales |
$ |
314,194 |
|
|
$ |
314,464 |
|
|
$ |
628,870 |
|
|
$ |
606,890 |
|
Cost of sales |
217,210 |
|
|
215,699 |
|
|
443,276 |
|
|
424,593 |
|
Gross profit |
96,984 |
|
|
98,765 |
|
|
185,594 |
|
|
182,297 |
|
Operating expenses: |
|
|
|
|
|
|
|
Selling, general and administrative expenses (SG&A) |
33,143 |
|
|
36,780 |
|
|
68,099 |
|
|
73,209 |
|
Research, development and engineering costs (RD&E) |
11,396 |
|
|
12,935 |
|
|
22,991 |
|
|
26,211 |
|
Other operating expenses (OOE) |
3,108 |
|
|
4,692 |
|
|
5,998 |
|
|
8,476 |
|
Total operating expenses |
47,647 |
|
|
54,407 |
|
|
97,088 |
|
|
107,896 |
|
Operating income |
49,337 |
|
|
44,358 |
|
|
88,506 |
|
|
74,401 |
|
Interest expense |
13,612 |
|
|
15,234 |
|
|
27,442 |
|
|
30,829 |
|
(Gain) loss on equity
investments, net |
1,611 |
|
|
(284 |
) |
|
1,652 |
|
|
(5,254 |
) |
Other income, net |
(718 |
) |
|
(2,387 |
) |
|
(552 |
) |
|
(1,427 |
) |
Income from continuing
operations before taxes |
34,832 |
|
|
31,795 |
|
|
59,964 |
|
|
50,253 |
|
Provision for income
taxes |
6,610 |
|
|
8,739 |
|
|
10,376 |
|
|
14,113 |
|
Income from continuing operations |
$ |
28,222 |
|
|
$ |
23,056 |
|
|
$ |
49,588 |
|
|
$ |
36,140 |
|
|
|
|
|
|
|
|
|
Discontinued operations: |
|
|
|
|
|
|
|
Income (loss) from
discontinued operations before taxes |
4,930 |
|
|
(1,374 |
) |
|
5,316 |
|
|
(7,623 |
) |
Provision for income
taxes |
95 |
|
|
1,660 |
|
|
178 |
|
|
377 |
|
Income (loss) from discontinued operations |
$ |
4,835 |
|
|
$ |
(3,034 |
) |
|
$ |
5,138 |
|
|
$ |
(8,000 |
) |
|
|
|
|
|
|
|
|
Net income |
$ |
33,057 |
|
|
$ |
20,022 |
|
|
$ |
54,726 |
|
|
$ |
28,140 |
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per
share: |
|
|
|
|
|
|
|
Income from continuing operations |
$ |
0.87 |
|
|
$ |
0.72 |
|
|
$ |
1.52 |
|
|
$ |
1.13 |
|
Income (loss) from discontinued operations |
$ |
0.15 |
|
|
$ |
(0.09 |
) |
|
$ |
0.16 |
|
|
$ |
(0.25 |
) |
Basic earnings per share |
$ |
1.01 |
|
|
$ |
0.62 |
|
|
$ |
1.68 |
|
|
$ |
0.88 |
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per
share: |
|
|
|
|
|
|
|
Income from continuing operations |
$ |
0.85 |
|
|
$ |
0.70 |
|
|
$ |
1.50 |
|
|
$ |
1.11 |
|
Income (loss) from discontinued operations |
$ |
0.15 |
|
|
$ |
(0.09 |
) |
|
$ |
0.16 |
|
|
$ |
(0.25 |
) |
Diluted earnings per share |
$ |
1.00 |
|
|
$ |
0.61 |
|
|
$ |
1.66 |
|
|
$ |
0.86 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding: |
|
|
|
|
|
|
|
Basic |
32,621 |
|
|
32,038 |
|
|
32,579 |
|
|
31,970 |
|
Diluted |
33,009 |
|
|
32,720 |
|
|
32,995 |
|
|
32,572 |
|
Condensed
Consolidated Balance Sheets - Unaudited |
(in
thousands) |
|
|
|
June 28, 2019 |
|
December 28,2018 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
15,922 |
|
|
$ |
25,569 |
|
Accounts receivable, net |
217,732 |
|
|
185,501 |
|
Inventories |
187,154 |
|
|
190,076 |
|
Prepaid expenses and other current assets |
24,978 |
|
|
15,104 |
|
Total current assets |
445,786 |
|
|
416,250 |
|
Property, plant and equipment,
net |
229,209 |
|
|
231,269 |
|
Goodwill |
831,368 |
|
|
832,338 |
|
Other intangible assets,
net |
791,472 |
|
|
812,338 |
|
Deferred income taxes |
4,099 |
|
|
3,937 |
|
Operating lease assets |
44,793 |
|
|
— |
|
Other long-term assets |
26,926 |
|
|
30,549 |
|
Total assets |
$ |
2,373,653 |
|
|
$ |
2,326,681 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Current portion of long-term debt |
$ |
37,500 |
|
|
$ |
37,500 |
|
Accounts payable |
73,120 |
|
|
57,187 |
|
Income taxes payable |
12,034 |
|
|
9,393 |
|
Accrued expenses and other current liabilities |
61,288 |
|
|
60,490 |
|
Total current liabilities |
183,942 |
|
|
164,570 |
|
Long-term debt |
825,438 |
|
|
888,007 |
|
Deferred income taxes |
201,350 |
|
|
203,910 |
|
Operating lease
liabilities |
39,788 |
|
|
— |
|
Other long-term
liabilities |
11,440 |
|
|
9,701 |
|
Total liabilities |
1,261,958 |
|
|
1,266,188 |
|
Stockholders’ equity: |
|
|
|
Common stock |
33 |
|
|
33 |
|
Additional paid-in capital |
697,648 |
|
|
691,083 |
|
Treasury stock |
(10,565 |
) |
|
(8,125 |
) |
Retained earnings |
398,648 |
|
|
344,498 |
|
Accumulated other comprehensive income |
25,931 |
|
|
33,004 |
|
Total stockholders’ equity |
1,111,695 |
|
|
1,060,493 |
|
Total liabilities and stockholders’ equity |
$ |
2,373,653 |
|
|
$ |
2,326,681 |
|
Condensed
Consolidated Statements of Cash Flows - Unaudited (a) |
(in
thousands) |
|
|
|
Six Months Ended |
|
June 28, 2019 |
|
June 29, 2018 |
Cash flows from
operating activities: |
|
|
|
Net income |
$ |
54,726 |
|
|
$ |
28,140 |
|
Adjustments to reconcile net
income to net cash provided by operating activities: |
|
|
|
Depreciation and amortization |
38,535 |
|
|
48,591 |
|
Debt related charges included in interest expense |
3,676 |
|
|
5,083 |
|
Stock-based compensation |
5,433 |
|
|
6,107 |
|
Non-cash (gain) loss on equity investments |
1,652 |
|
|
(763 |
) |
Other non-cash gains |
(311 |
) |
|
(2,307 |
) |
Deferred income taxes |
(1,126 |
) |
|
8,894 |
|
Gain on sale of discontinued operations |
(4,974 |
) |
|
— |
|
Changes in operating assets
and liabilities: |
|
|
|
Accounts receivable |
(30,545 |
) |
|
(11,306 |
) |
Inventories |
2,846 |
|
|
(20,948 |
) |
Prepaid expenses and other assets |
(12,942 |
) |
|
3,306 |
|
Accounts payable |
16,289 |
|
|
8,898 |
|
Accrued expenses and other liabilities |
(8,593 |
) |
|
(3,929 |
) |
Income taxes payable |
2,884 |
|
|
(2,547 |
) |
Net cash provided by operating activities |
67,550 |
|
|
67,219 |
|
Cash flows from
investing activities: |
|
|
|
Acquisition of property, plant
and equipment |
(15,506 |
) |
|
(19,224 |
) |
Proceeds from sale of
property, plant and equipment |
5 |
|
|
960 |
|
Purchase of equity
investments |
(327 |
) |
|
(831 |
) |
Proceeds from sale of
discontinued operations |
4,734 |
|
|
— |
|
Net cash used in investing activities |
(11,094 |
) |
|
(19,095 |
) |
Cash flows from
financing activities: |
|
|
|
Principal payments of
long-term debt |
(80,750 |
) |
|
(75,062 |
) |
Proceeds from issuance of
long-term debt |
15,000 |
|
|
— |
|
Proceeds from the exercise of
stock options |
1,600 |
|
|
3,625 |
|
Payment of debt issuance and
redemption costs |
— |
|
|
(688 |
) |
Tax withholdings related to
net share settlements of restricted stock unit awards |
(2,123 |
) |
|
(2,206 |
) |
Other financing
activities |
— |
|
|
(192 |
) |
Net cash used in financing activities |
(66,273 |
) |
|
(74,523 |
) |
Effect of foreign currency
exchange rates on cash and cash equivalents |
170 |
|
|
2,363 |
|
Net decrease in cash and cash
equivalents |
(9,647 |
) |
|
(24,036 |
) |
Cash and cash equivalents,
beginning of period |
25,569 |
|
|
44,096 |
|
Cash and cash equivalents, end
of period |
$ |
15,922 |
|
|
$ |
20,060 |
|
(a) Condensed Consolidated Statements of
Cash Flows - Unaudited includes cash flows related to discontinued
operations.
Reconciliations of Non-GAAP Measures from Continuing
Operations
Table A: Income (Loss) from Continuing Operations and
Diluted EPS Reconciliations(in thousands except per share
amounts)
|
Three Months Ended |
|
June 28, 2019 |
|
June 29, 2018 |
|
Pre-Tax |
|
Net ofTax |
|
PerDilutedShare |
|
Pre-Tax |
|
Net ofTax |
|
PerDilutedShare |
As reported income from continuing operations (GAAP) |
$ |
34,832 |
|
|
$ |
28,222 |
|
|
$ |
0.85 |
|
|
$ |
31,795 |
|
|
$ |
23,056 |
|
|
$ |
0.70 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangibles(a) |
9,831 |
|
|
7,778 |
|
|
0.24 |
|
|
10,519 |
|
|
8,296 |
|
|
0.25 |
|
Certain legal expenses (SG&A)(a)(b) |
680 |
|
|
537 |
|
|
0.02 |
|
|
476 |
|
|
376 |
|
|
0.01 |
|
Strategic reorganization and alignment (OOE)(a)(c) |
1,656 |
|
|
1,287 |
|
|
0.04 |
|
|
3,727 |
|
|
2,950 |
|
|
0.09 |
|
Manufacturing alignment to support growth (OOE)(a)(d) |
561 |
|
|
393 |
|
|
0.01 |
|
|
1,103 |
|
|
815 |
|
|
0.02 |
|
Consolidation and optimization expenses (OOE)(a)(e) |
— |
|
|
— |
|
|
— |
|
|
(14 |
) |
|
(10 |
) |
|
— |
|
Asset dispositions, severance and other (OOE)(a)(f) |
891 |
|
|
699 |
|
|
0.02 |
|
|
(124 |
) |
|
(106 |
) |
|
— |
|
(Gain) loss on equity investments, net(a) |
1,611 |
|
|
1,273 |
|
|
0.04 |
|
|
(284 |
) |
|
(225 |
) |
|
(0.01 |
) |
Loss on extinguishment of debt(a)(g) |
562 |
|
|
443 |
|
|
0.01 |
|
|
417 |
|
|
329 |
|
|
0.01 |
|
LSA adjustments(a)(h) |
— |
|
|
— |
|
|
— |
|
|
(3,283 |
) |
|
(2,594 |
) |
|
(0.08 |
) |
Tax adjustments(i) |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
1,857 |
|
|
0.06 |
|
Adjusted income from
continuing operations (Non-GAAP) |
$ |
50,624 |
|
|
$ |
40,632 |
|
|
$ |
1.23 |
|
|
$ |
44,332 |
|
|
$ |
34,744 |
|
|
$ |
1.06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted average
shares for adjusted EPS |
|
|
33,009 |
|
|
|
|
|
|
32,720 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
June 28, 2019 |
|
June 29, 2018 |
|
Pre-Tax |
|
Net ofTax |
|
PerDilutedShare |
|
Pre-Tax |
|
Net ofTax |
|
PerDilutedShare |
As reported income from
continuing operations (GAAP) |
$ |
59,964 |
|
|
$ |
49,588 |
|
|
$ |
1.50 |
|
|
$ |
50,253 |
|
|
$ |
36,140 |
|
|
$ |
1.11 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangibles(a) |
19,685 |
|
|
15,574 |
|
|
0.47 |
|
|
21,172 |
|
|
16,693 |
|
|
0.51 |
|
Certain legal expenses (SG&A)(a)(b) |
2,076 |
|
|
1,640 |
|
|
0.05 |
|
|
797 |
|
|
630 |
|
|
0.02 |
|
Strategic reorganization and alignment (OOE)(a)(c) |
3,390 |
|
|
2,637 |
|
|
0.08 |
|
|
5,781 |
|
|
4,577 |
|
|
0.14 |
|
Manufacturing alignment to support growth (OOE)(a)(d) |
1,146 |
|
|
807 |
|
|
0.02 |
|
|
1,616 |
|
|
1,184 |
|
|
0.04 |
|
Consolidation and optimization expenses (OOE)(a)(e) |
— |
|
|
— |
|
|
— |
|
|
561 |
|
|
445 |
|
|
0.01 |
|
Asset dispositions, severance and other (OOE)(a)(f) |
1,462 |
|
|
1,152 |
|
|
0.03 |
|
|
518 |
|
|
364 |
|
|
0.01 |
|
(Gain) loss on equity investments, net(a) |
1,652 |
|
|
1,305 |
|
|
0.04 |
|
|
(5,254 |
) |
|
(4,151 |
) |
|
(0.13 |
) |
Loss on extinguishment of debt(a)(g) |
974 |
|
|
769 |
|
|
0.02 |
|
|
1,474 |
|
|
1,164 |
|
|
0.04 |
|
LSA adjustments(a)(h) |
— |
|
|
— |
|
|
— |
|
|
(6,119 |
) |
|
(4,834 |
) |
|
(0.15 |
) |
Tax adjustments(i) |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
2,951 |
|
|
0.09 |
|
Adjusted income from
continuing operations (Non-GAAP) |
$ |
90,349 |
|
|
$ |
73,472 |
|
|
$ |
2.23 |
|
|
$ |
70,799 |
|
|
$ |
55,163 |
|
|
$ |
1.69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted average
shares for adjusted EPS |
|
|
32,995 |
|
|
|
|
|
|
32,572 |
|
|
|
(a) The difference between pre-tax and net of
tax amounts is the estimated tax impact related to the respective
adjustment. Net of tax amounts are computed using a 21% U.S.
tax rate, and the statutory tax rates in Mexico, Netherlands,
Uruguay, Ireland and Switzerland, as adjusted for the existence of
net operating losses (“NOLs”). Amortization of intangibles
and other operating expense for 2018 have also been adjusted to
reflect the estimated impact relating to our disallowed deduction
of the GILTI tax, as described in footnote (i) below.
Expenses that are not deductible for tax purposes (i.e. permanent
tax differences) are added back at 100%.
(b) In 2013, we filed suit against AVX
Corporation alleging they were infringing our intellectual
property. Given the complexity and significant costs incurred
pursuing this litigation, we are excluding these litigation
expenses from adjusted amounts. This matter proceeded to trial
during the first quarter of 2016 and again in the third quarter of
2017 that resulted in a jury awarding damages in the amount of
$37.5 million. In March 2018, the court vacated that damage
award and ordered a new trial on damages. In the January 2019
retrial on damages, the jury awarded damages in the amount of $22.2
million. On July 31, 2019, the U. S. District Court for the
District of Delaware entered an order in the AVX litigation denying
AVX’s post-trial motion to overturn the jury verdict in our
favor. This proceeding is subject to post-trial
proceedings. To date, no gains have been recognized in
connection with this litigation. The second quarter 2019 also
includes costs associated with responding to a subpoena in
connection with a legal matter to which we are a non-party
witness.
(c) Amounts include expenses related to
implementing our strategy that is designed to better align our
resources in order to invest to grow, protect, preserve and to
enhance the profitability of our portfolio of products, including
focusing our investment in RD&E and manufacturing, improving
our business processes and redirecting investments away from
projects where the market does not justify the investment.
During 2019 and 2018, we incurred charges related to this strategy,
which primarily consisted of severance costs and fees for
professional services.
(d) Includes expenses related to several
initiatives designed to reduce costs, improve operating
efficiencies and increase manufacturing capacity to accommodate
growth. The plan involves the relocation of certain
manufacturing operations and expansion of certain of our
facilities.
(e) During 2018, we incurred costs primarily
related to the closure of our Clarence, NY facility.
(f) Amounts include expenses related to other
initiatives not described above, which relate primarily to
integration and operational initiatives to reduce costs and improve
operational efficiencies.
(g) Represents debt extinguishment charges in
connection with pre-payments made on our Term Loan B Facility,
which are included in interest expense.
(h) Reflects the net impact of the LSAs entered
into as of the closing of the divestiture of the AS&O product
line. These LSAs govern the sale of products supplied by
Viant to the Company for further resale to customers and by the
Company to Viant for further resale to customers.
(i) The tax adjustment for 2018 represents the
estimated impact relating to our disallowed deduction of the GILTI
tax, as mandated by the Tax Reform Act. This disallowed
deduction of the GILTI tax (approximately 50% of the total GILTI
tax) is due to the Company making use of its U.S. NOLs during
2018. This adjustment makes our Adjusted Diluted EPS from
continuing operations more comparable with other global companies
that are not subject to this disallowed GILTI tax deduction and
more comparable to the Company’s results following the full
utilization of its U.S. NOLs.
Table B: EBITDA and Sales Reconciliations(in
thousands)
|
Three Months Ended |
|
Six Months Ended |
|
June 28, 2019 |
|
June 29, 2018 |
|
June 28, 2019 |
|
June 29, 2018 |
Income from continuing operations (GAAP) |
$ |
28,222 |
|
|
$ |
23,056 |
|
|
$ |
49,588 |
|
|
$ |
36,140 |
|
|
|
|
|
|
|
|
|
Interest expense |
13,612 |
|
|
15,234 |
|
|
27,442 |
|
|
30,829 |
|
Provision for income
taxes |
6,610 |
|
|
8,739 |
|
|
10,376 |
|
|
14,113 |
|
Depreciation |
9,046 |
|
|
10,006 |
|
|
18,850 |
|
|
19,969 |
|
Amortization of intangibles
(excluding OOE) |
9,831 |
|
|
10,519 |
|
|
19,685 |
|
|
21,172 |
|
EBITDA from continuing operations (Non-GAAP) |
67,321 |
|
|
67,554 |
|
|
125,941 |
|
|
122,223 |
|
Certain legal expenses |
680 |
|
|
476 |
|
|
2,076 |
|
|
797 |
|
Stock-based compensation
(excluding OOE) |
2,673 |
|
|
2,199 |
|
|
5,386 |
|
|
5,178 |
|
Strategic reorganization and
alignment |
1,656 |
|
|
3,727 |
|
|
3,390 |
|
|
5,781 |
|
Manufacturing alignment to
support growth |
561 |
|
|
1,103 |
|
|
1,146 |
|
|
1,616 |
|
Consolidation and optimization
expenses |
— |
|
|
(14 |
) |
|
— |
|
|
561 |
|
Asset dispositions, severance
and other |
891 |
|
|
(124 |
) |
|
1,462 |
|
|
518 |
|
(Gain) loss on equity
investments, net |
1,611 |
|
|
(284 |
) |
|
1,652 |
|
|
(5,254 |
) |
LSA adjustments |
— |
|
|
(3,283 |
) |
|
— |
|
|
(6,119 |
) |
Adjusted EBITDA from
continuing operations (Non-GAAP) |
$ |
75,393 |
|
|
$ |
71,354 |
|
|
$ |
141,053 |
|
|
$ |
125,301 |
|
|
|
|
|
|
|
|
|
Total Sales (GAAP) |
$ |
314,194 |
|
|
$ |
314,464 |
|
|
$ |
628,870 |
|
|
$ |
606,890 |
|
LSA adjustments |
— |
|
|
(1,308 |
) |
|
— |
|
|
(2,003 |
) |
Adjusted sales from continuing
operations (Non-GAAP) |
$ |
314,194 |
|
|
$ |
313,156 |
|
|
$ |
628,870 |
|
|
$ |
604,887 |
|
|
|
|
|
|
|
|
|
Adjusted EBITDA margin |
24 |
% |
|
23 |
% |
|
22 |
% |
|
21 |
% |
Table C: Organic Sales from Continuing Operations Growth
Rate Reconciliation (% Change)
|
GAAPReportedGrowth |
|
Impact ofLSAs(a) |
|
Impact ofForeignCurrency(b) |
|
Non-GAAPOrganicGrowth |
QTD Change (2Q 2019
vs. 2Q 2018) |
|
|
|
|
|
|
|
Medical
Sales |
|
|
|
|
|
|
|
Cardio & Vascular |
1.1 |
% |
|
— |
% |
|
0.5 |
% |
|
1.6 |
% |
Cardiac & Neuromodulation |
(1.3 |
)% |
|
— |
|
|
— |
|
|
(1.3 |
)% |
Advanced Surgical, Orthopedics & Portable Medical |
(6.1 |
)% |
|
3.7 |
% |
|
0.1 |
% |
|
(2.3 |
)% |
Total Medical Sales |
(0.6 |
)% |
|
0.4 |
% |
|
0.2 |
% |
|
— |
% |
Non-Medical
Sales |
11.0 |
% |
|
— |
|
|
— |
|
|
11.0 |
% |
Total Sales |
(0.1 |
)% |
|
0.4 |
% |
|
0.3 |
% |
|
0.6 |
% |
|
|
|
|
|
|
|
|
YTD Change (6M 2019
vs. 6M 2018) |
|
|
|
|
|
|
|
Medical
Sales |
|
|
|
|
|
|
|
Cardio & Vascular |
6.1 |
% |
|
— |
% |
|
0.5 |
% |
|
6.6 |
% |
Cardiac & Neuromodulation |
2.9 |
% |
|
— |
|
|
— |
|
|
2.9 |
% |
Advanced Surgical, Orthopedics & Portable Medical |
(6.5 |
)% |
|
2.8 |
% |
|
0.1 |
% |
|
(3.6 |
)% |
Total Medical Sales |
3.4 |
% |
|
0.3 |
% |
|
0.3 |
% |
|
4.0 |
% |
Non-Medical
Sales |
9.2 |
% |
|
— |
|
|
— |
|
|
9.2 |
% |
Total Sales |
3.6 |
% |
|
0.4 |
% |
|
0.2 |
% |
|
4.2 |
% |
(a) Reflects the net impact of the LSAs entered
into as of the closing of the divestiture of the AS&O product
line.
(b) Second quarter and year-to-date 2019 GAAP
sales were negatively impacted by $0.7 million and $1.6 million,
respectively, due to foreign currency exchange rate
fluctuations, primarily in our Cardio & Vascular product
line.
Table D: Non-GAAP Organic Growth Rate Reconciliation (%
Change)
|
GAAPReportedGrowth(a) |
|
Impact
ofNon-GAAPAdjustment(b) |
|
Impact ofForeignCurrency(c) |
|
Non-GAAPOrganicGrowth |
QTD Change (2Q 2019
vs. 2Q 2018) |
|
|
|
|
|
|
|
EBITDA from continuing operations |
(0.3 |
)% |
|
6.0 |
% |
|
2.9 |
% |
|
8.6 |
% |
Income from continuing
operations |
22.4 |
% |
|
(5.5 |
)% |
|
5.5 |
% |
|
22.4 |
% |
Diluted EPS from continuing
operations |
21.4 |
% |
|
(5.4 |
)% |
|
5.8 |
% |
|
21.8 |
% |
|
|
|
|
|
|
|
|
YTD Change (6M 2019
vs. 6M 2018) |
|
|
|
|
|
|
|
EBITDA from continuing
operations |
3.0 |
% |
|
9.6 |
% |
|
0.7 |
% |
|
13.3 |
% |
Income from continuing
operations |
37.2 |
% |
|
(4.0 |
)% |
|
1.4 |
% |
|
34.6 |
% |
Diluted EPS from continuing
operations |
35.1 |
% |
|
(3.1 |
)% |
|
0.7 |
% |
|
32.7 |
% |
(a) EBITDA from continuing operations is a non-GAAP
measure. See Table B for a reconciliation to the most
comparable GAAP measure.
(b) Represents the impact to our growth rate from our Non-GAAP
adjustments. See Tables A and B for further detail on these
items.
(c) Represents the impact to our growth rate due to changes in
foreign currency exchange rates realized in income and reported in
other income, net in the consolidated statements of operations.
Table E: Supplemental Financial Items Affecting Cash
Flow(dollars in millions)
|
|
2019Outlook |
|
2018Actual |
|
Capital Expenditures |
|
$50 - $55 |
|
$44 |
|
|
Depreciation and
Amortization |
|
$75 - $85 |
|
$82 |
|
|
Stock-Based Compensation |
|
$10 - $12 |
|
$10 |
|
|
Other Operating Expense |
|
$10 - $15 |
|
$16 |
|
|
Adjusted Effective Tax
Rate |
|
17.5% - 19.5% |
|
$18.5 |
% |
|
Cash Tax Payments |
|
$30 - $35 |
|
$23 |
|
|
Integer (NYSE:ITGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Integer (NYSE:ITGR)
Historical Stock Chart
From Sep 2023 to Sep 2024